AAAAAA

   
Results: 1-8 |
Results: 8
RITUXIMAB CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY FOR RELAPSEDINDOLENT LYMPHOMA - HALF OF PATIENTS RESPOND TO A 4-DOSE TREATMENT PROGRAM
Authors: MCLAUGHLIN P GRILLOLOPEZ AJ LINK BK LEVY R CZUCZMAN MS WILLIAMS ME HEYMAN MR BENCEBRUCKLER I WHITE CA CABANILLAS F JAIN V HO AD LISTER J WEY K SHEN D DALLAIRE BK
Citation: P. Mclaughlin et al., RITUXIMAB CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY FOR RELAPSEDINDOLENT LYMPHOMA - HALF OF PATIENTS RESPOND TO A 4-DOSE TREATMENT PROGRAM, Journal of clinical oncology, 16(8), 1998, pp. 2825-2833
ANTI-CD3-BASED BISPECIFIC ANTIBODY DESIGNED FOR THERAPY OF HUMAN B-CELL MALIGNANCY CAN INDUCE T-CELL ACTIVATION BY ANTIGEN-DEPENDENT AND ANTIGEN-INDEPENDENT MECHANISMS
Authors: LINK BK KOSTELNY SA COLE MS FUSSELMAN WP TSO JY WEINER GJ
Citation: Bk. Link et al., ANTI-CD3-BASED BISPECIFIC ANTIBODY DESIGNED FOR THERAPY OF HUMAN B-CELL MALIGNANCY CAN INDUCE T-CELL ACTIVATION BY ANTIGEN-DEPENDENT AND ANTIGEN-INDEPENDENT MECHANISMS, International journal of cancer, 77(2), 1998, pp. 251-256
IDEC-C2B8 ANTI-CD20 ANTIBODY - FINAL REPORT ON A PHASE-III PIVOTAL TRIAL IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA (LG F NHL)/
Authors: MCLAUGHLIN P CABANILLAS F GRILLOLOPEZ AJ LINK BK LEVY R CRUCZMAN M HEYMAN MR WILLIAMS M JAIN W BENCEBRUCKLER I HO AD LISTER J ROSENBERG J DALLAIRE BK SHEN D
Citation: P. Mclaughlin et al., IDEC-C2B8 ANTI-CD20 ANTIBODY - FINAL REPORT ON A PHASE-III PIVOTAL TRIAL IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA (LG F NHL)/, Blood, 88(10), 1996, pp. 349-349
ANTI-CD20 ANTIBODY (MAB), IDEC-C2B8 - CLEARANCE OF BCL-2 T(14-18) POSITIVE CELLS FROM PERIPHERAL-BLOOD (PB) AND BONE-MARROW (BM) IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA (LG F NHL)/
Authors: CABANILLAS F GRILLOLOPEZ AJ MCLAUGHLIN P LINK BK LEVY R CZUCZMAN M HEYMAN MR WILLIAMS M JAIN V BENCEBRUCKLER I HO AD LISTER J ROGER J SHEN D VARNS C
Citation: F. Cabanillas et al., ANTI-CD20 ANTIBODY (MAB), IDEC-C2B8 - CLEARANCE OF BCL-2 T(14-18) POSITIVE CELLS FROM PERIPHERAL-BLOOD (PB) AND BONE-MARROW (BM) IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA (LG F NHL)/, Blood, 88(10), 1996, pp. 351-351
PRODUCTION AND INITIAL EVALUATION OF A HUMANIZED BSF(AB')(2) ANTI-CD3-BASED BISPECIFIC MONOCLONAL-ANTIBODY DESIGNED FOR THERAPY OF HUMAN B-CELL MALIGNANCIES
Authors: LINK BK MOES R FUSSELMAN WP KOSTELNY SA COLE MS TSO JY WEINER GJ
Citation: Bk. Link et al., PRODUCTION AND INITIAL EVALUATION OF A HUMANIZED BSF(AB')(2) ANTI-CD3-BASED BISPECIFIC MONOCLONAL-ANTIBODY DESIGNED FOR THERAPY OF HUMAN B-CELL MALIGNANCIES, Blood, 86(10), 1995, pp. 1264-1264
THE ROLE OF T-CELL ACTIVATION IN ANTI-CD3 X ANTITUMOR BISPECIFIC ANTIBODY THERAPY
Authors: WEINER GJ KOSTELNY SA HILLSTROM JR COLE MS LINK BK WANG SL TSO JY
Citation: Gj. Weiner et al., THE ROLE OF T-CELL ACTIVATION IN ANTI-CD3 X ANTITUMOR BISPECIFIC ANTIBODY THERAPY, The Journal of immunology, 152(5), 1994, pp. 2385-2392
THE ROLE OF ANTIBODY FC AND T-CELL ACTIVATION IN CD3-BASED BISPECIFICMONOCLONAL-ANTIBODY THERAPY
Authors: WEINER GJ KOSTELNY SA HILLSTROM JR COLE MS LINK BK WANG SL TSO JY
Citation: Gj. Weiner et al., THE ROLE OF ANTIBODY FC AND T-CELL ACTIVATION IN CD3-BASED BISPECIFICMONOCLONAL-ANTIBODY THERAPY, Blood, 82(10), 1993, pp. 10000323-10000323
PRODUCTION AND CHARACTERIZATION OF A BISPECIFIC IGG CAPABLE OF INDUCING T-CELL-MEDIATED LYSIS OF MALIGNANT B-CELLS
Authors: LINK BK WEINER GJ
Citation: Bk. Link et Gj. Weiner, PRODUCTION AND CHARACTERIZATION OF A BISPECIFIC IGG CAPABLE OF INDUCING T-CELL-MEDIATED LYSIS OF MALIGNANT B-CELLS, Blood, 81(12), 1993, pp. 3343-3349
Risultati: 1-8 |